down arrow

Daré Bioscience, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23666P1012
USD
2.75
-0.16 (-5.5%)

May 08

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.662.94

52 Week

1.279.19
Valuation
Technical
Day's Volume

CASH

91.55 k

Shareholding (Dec 2025)

FII

0.28%

Held by 6 FIIs

DII

95.64%

Held by 4 DIIs

Promoter

0.00%

How big is Daré Bioscience, Inc.?

22-Jun-2025

As of Jun 18, Daré Bioscience, Inc. has a market capitalization of 25.53 million and reported net sales of 0.10 million with a net profit of -2.93 million over the latest four quarters. Shareholder's funds are at -6.01 million, and total assets amount to 22.10 million.

As of Jun 18, Daré Bioscience, Inc. has a market capitalization of 25.53 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.10 million, while the sum of net profit for the same period is -2.93 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -6.01 million, and the total assets amount to 22.10 million.

View full answer

What does Daré Bioscience, Inc. do?

22-Jun-2025

Daré Bioscience, Inc. is a micro-cap healthcare company focused on developing and commercializing products for women’s reproductive health. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $25.53 million.

Overview:<BR>Daré Bioscience, Inc. is a healthcare company focused on the development and commercialization of products in women’s reproductive health, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 25.53 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.33 <BR>Return on Equity: 29.81% <BR>Price to Book: -2.67<BR><BR>Contact Details:<BR>Address: 3655 Nobel Dr Ste 260, SAN DIEGO CA : 92122-1050 <BR>Tel: 1 858 9267655 <BR>Website: https://www.darebioscience.com/

View full answer

Who are in the management team of Daré Bioscience, Inc.?

22-Jun-2025

As of March 2022, the management team of Daré Bioscience, Inc. is led by Dr. William Rastetter (Independent Chairman) and Ms. Sabrina Johnson (President and CEO), supported by several independent directors including Dr. Cheryl Blanchard, Ms. Jessica Grossman, Mr. Steve Hall, Dr. Susan Kelley, and Mr. Gregory Matz.

As of March 2022, the management team of Daré Bioscience, Inc. includes the following individuals:<BR><BR>- Dr. William Rastetter, who serves as the Independent Chairman of the Board.<BR>- Ms. Sabrina Johnson, who holds the positions of President, Chief Executive Officer, Secretary, and Director.<BR>- Dr. Cheryl Blanchard, who is an Independent Director.<BR>- Ms. Jessica Grossman, also an Independent Director.<BR>- Mr. Steve Hall, another Independent Director.<BR>- Dr. Susan Kelley, who serves as an Independent Director.<BR>- Mr. Gregory Matz, who is an Independent Director.<BR><BR>In summary, the management team is led by Dr. William Rastetter and Ms. Sabrina Johnson, with several independent directors supporting the board.

View full answer

Is Daré Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2025, Daré Bioscience, Inc. is considered overvalued with negative financial metrics and a valuation grade of "does not qualify," significantly underperforming compared to peers and the S&P 500.

As of 13 May 2025, the valuation grade for Daré Bioscience, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, with a Price to Book Value of -2.96 and an EV to EBITDA of -1.13, both of which reflect negative financial metrics. Additionally, the company's P/E ratio is not applicable due to its loss-making status.<BR><BR>In comparison with peers, Daré Bioscience's valuation metrics are notably worse than those of Rezolute, Inc., which has a P/E of -4.90 and an EV to EBITDA of -3.46, and SELLAS Life Sciences Group, Inc., with a P/E of -5.74 and an EV to EBITDA of -4.57. The stark contrast in these ratios suggests that Daré is not only underperforming relative to its peers but also struggling to establish a viable valuation. Furthermore, the company's stock has significantly lagged behind the S&P 500, with a one-year return of -50.90% compared to the index's 10.26%, reinforcing the notion of overvaluation.

View full answer

Is Daré Bioscience, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Daré Bioscience, Inc. shows a mildly bearish technical trend with mixed signals across indicators, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -33.33% and -35.60%, respectively.

As of 2 September 2025, the technical trend for Daré Bioscience, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The weekly Bollinger Bands and KST are bearish, but the monthly KST is mildly bullish. The daily moving averages are bearish, indicating short-term weakness. The Dow Theory shows a mildly bullish trend on the weekly timeframe, but no trend on the monthly. Overall, the technical stance is mildly bearish, with mixed signals across different indicators.<BR><BR>In terms of performance, the company has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -33.33% compared to the S&P 500's 12.22%, and a one-year return of -35.60% versus the S&P 500's 17.14%.

View full answer

Compare Daré Bioscience, Inc. with Similar Stocks

Fortress Biotech, Inc.Sol-Gel Technologies Ltd.Kineta, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROCE of 0%

  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2

Flat results in Sep 25

3

Risky -

4

Falling Participation by Institutional Investors

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 21 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-5.38

stock-summary
Return on Equity

-582.07%

stock-summary
Price to Book

7.35

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Dec 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
62.72%
0%
62.72%
6 Months
50.27%
0%
50.27%
1 Year
-5.82%
0%
-5.82%
2 Years
-25.38%
0%
-25.38%
3 Years
175.0%
0%
175.0%
4 Years
-78.98%
0%
-78.98%
5 Years
-83.39%
0%
-83.39%

Daré Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.98%
EBIT Growth (5y)
1.98%
EBIT to Interest (avg)
-26.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
-0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.52%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.35
EV to EBIT
-0.34
EV to EBITDA
-0.37
EV to Capital Employed
-0.45
EV to Sales
5.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-582.07%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (4.08%)

Foreign Institutions

Held by 6 Foreign Institutions (0.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Daré Bioscience, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -226.83% vs 86.42% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.40",
          "val2": "-22.90",
          "chgp": "50.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.90",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-4.10",
          "chgp": "-226.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,155.10%",
          "val2": "-2,396,922.00%",
          "chgp": "2,38,376.69%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.40
-22.90
50.22%
Interest
0.80
0.90
-11.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.40
-4.10
-226.83%
Operating Profit Margin (Excl OI)
-13,155.10%
-2,396,922.00%
2,38,376.69%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -226.83% vs 86.42% in Dec 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Daré Bioscience, Inc. stock-summary
stock-summary
Daré Bioscience, Inc.
Pharmaceuticals & Biotechnology
Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
Company Coordinates stock-summary
Company Details
3655 Nobel Dr Ste 260 , SAN DIEGO CA : 92122-1050
stock-summary
Tel: 1 858 9267655
stock-summary
https://www.darebioscience.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."